HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): James A. Magovern Ignacio Y. Christlieb Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magovern, J. A. Articles by Kao, R. L. Search for Related Content PubMed PubMed Citation Articles by Magovern, J. A. Articles by Kao, R. L.

Ann Thorac Surg 1992;53:861-863
© 1992 The Society of Thoracic Surgeons

---

Articles

A model of left ventricular dysfunction caused by intracoronary adriamycin

^a Allegheny-Singer Research Institute, Allegheny General Hospital, The Medical College of Pennsylvania, Pittsburgh, Pennsylvania, USA
^b Hillenbrand Biomedical Engineering Center, Purdue University, West Lafayette, Indiana USA

Accepted for publication October 28, 1991.

^_* Address reprint requests to Dr Magovern, Department of Surgery, Allegheny General Hospital, 320 E North Avc, Pittsburgh, PA 15212.

Experimental evaluation of new therapy for congestive heart failure has been hampered by the lack of a simple and reliable animal model of heart failure. This study was undertaken to develop a canine model of chronic left ventricular dysfunction. A left thoracotomy was performed in 9 adult mongrel dogs. A 1.5-mm Silastic (Dow Corning) catheter with an attached subcutaneous access port was positioned in the left main coronary artery. Six animals received five weekly infusions of Adriamycin (doxorubicin hydrochloride) (10 mg/wk), and 3 received saline solution. Hemodynamic studies were performed before insertion of the catheter and 2 weeks after completion of the infusions. In animals that received Adriamycin, rest ejection fraction declined from 0.54 ± 0.03 to 0.35 ± 0.03, cardiac output fell from 5.6 ± 0.6 to 3.9 ±0.5 L/min, and left ventricular end-diastolic volume increased from 76 ± 9 to 99 ± 12 mL (p < 0.05). There was a small increase in right atrial pressure (2.7 ± 1 versus 5.7 ± 1 mm Hg) but no change in right ventricular ejection fraction (0.31 ± 0.04 versus 0.30 ± 0.03). In no animal did alopecia, weight loss, neutropenia, or anemia develop. Histological changes consistent with Adriamycin-induced cardiac toxicity were found in each dog. No significant hemodynamic or histological changes occurred in the control animals. Administration of Adriamycin into the left main coronary artery causes left ventricular dysfunction without resulting in systemic side effects or compromising right ventricular function. This animal model could be used to evaluate the effects of new possible therapy, such as cardiomyoplasty, on left ventricular failure.

This article has been cited by other articles:

				N. Borenstein, V. Chetboul, P. Bruneval, M. Hekmati, R. Tissier, L. Behr, G. Derumeaux, and D. Montarras Non-cultured cell transplantation in an ovine model of non-ischemic heart failure Eur J Cardiothorac Surg, March 1, 2007; 31(3): 444 - 451. [Abstract] [Full Text] [PDF]

				S. Christiansen and R. Autschbach Doxorubicin in experimental and clinical heart failure Eur J Cardiothorac Surg, October 1, 2006; 30(4): 611 - 616. [Abstract] [Full Text] [PDF]

				M. Vaynblat, H. R. Shah, D. Bhaskaran, G. Ramdev, W. J. Davis III, J. N. Cunningham Jr., and M. Chiavarelli Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin Eur J Heart Fail, October 1, 2002; 4(5): 583 - 586. [Abstract] [Full Text] [PDF]

				G. Hasenfuss Animal models of human cardiovascular disease, heart failure and hypertrophy Cardiovasc Res, July 1, 1998; 39(1): 60 - 76. [Abstract] [Full Text] [PDF]

				Y. Toyoda, M. Okada, and M. A. Kashem A canine model of dilated cardiomyopathy induced by repetitive intracoronary doxorubicin administration J. Thorac. Cardiovasc. Surg., June 1, 1998; 115(6): 1367 - 1374. [Abstract] [Full Text] [PDF]

				R. R. Waterford, J. R. Van Camp, M. A. Gallagher, M. T. Anderson, S. F. Bolling, and L. A. Brunsting III Adjustable Model of Chronic Left Ventricular Dysfunction Ann. Thorac. Surg., December 1, 1997; 64(6): 1682 - 1685. [Abstract] [Full Text]

				M. Vaynblat, M. Chiavarelli, H. R. Shah, G. Ramdev, M. Aron, Z. Zisbrod, and J. N. Cunningham Jr Cardiac Binding in Experimental Heart Failure Ann. Thorac. Surg., July 1, 1997; 64(1): 81 - 85. [Abstract] [Full Text]